Latest News

Cambridge Health Saudi Arabia expects its licensed capacity to approach 500 beds once ongoing expansion projects at Cambridge Hospital Jeddah are completed and additional beds at Cambridge Hospital Dhahran receive regulatory approval.

The FDA has classified the action as a Class II recall, indicating that the affected product may cause temporary or medically reversible adverse health effects, although the likelihood of serious health consequences remains low.

The approval authorises the company to collect plasma in Indonesia and process it through its global manufacturing network while the country develops its own plasma infrastructure.

The investment package was launched in collaboration with the Ministry of Health and the Public Authority for Special Economic Zones and Free Zones.

The agreements were signed during a ceremony attended by senior government officials, including Bahrain’s Minister of Education, Dr Mohammed Mubarak Juma, and Saudi Fund for Development (SFD) Chief Executive Officer Sultan Al Marshad.

The agreement was signed by Total CX Interim Chief Executive Officer Aseel Mattar and Ibn Al Nafees Hospital Chief Executive Officer Rahma Jaberi during a ceremony in Bahrain.

The latest agreement aligns with Teva’s broader “Pivot to Growth” strategy, which focuses on strengthening its innovative medicines and biosimilars businesses through collaborations that expand its global pipeline.

The setback comes at a crucial time as competition intensifies in the fast-growing market for lower-cost versions of Novo Nordisk’s blockbuster diabetes and obesity medicine.

Breast cancer remains the country’s most commonly diagnosed cancer, accounting for 5,822 new cases, or 16.2% of all cancers.

The partnership combines GCLS’s expertise as the world’s first higher education institution dedicated exclusively to longevity science with GMU’s academic resources and Thumbay Healthcare’s extensive clinical network across the region.